Safety and Performance Study of Large Hole Vascular Closure Device FIV

Inclusion Criteria: * Over 18 years of age. * Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements. * Clinically indicated for an endovascular procedure using a common femoral arteriotomy created by a 12 - 20 F sheath. Exclusion Criteria: * Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of less than six months. * Evidence of systemic bacterial or cutaneous infection, including groin infection. * Known bleeding diathesis, definite or potential coagulopathy, platelet count \< 100,000/μl or patients on long term anticoagulants with an INR greater than 1.2 at time of procedure or known type II heparin-induced thrombocytopenia. * Severe; claudication or peripheral vascular disease (e.g. Rutherford category 3 or greater or ABI \< 0.5), documented untreated iliac artery diameter stenosis \> 50% or previous bypass surgery/stent placement in the common femoral artery of ipsilateral limb. * Known allergy to any of the materials used in the PerQseal®. * Subject has undergone a percutaneous procedure using a non-absorbable vascular closure device (excluding suture mediated) for haemostasis in the ipsilateral target leg. * Patients that have undergone a percutaneous procedure in the ipsilateral leg, within the previous 30 days. * Patients that have undergone a percutaneous procedure using an absorbable intravascular closure device for haemostasis, in the ipsilateral leg, within the previous 90 days. * Evidence of arterial diameter stenosis \> 20% or anterior or circumferential calcification within 20 mm proximal or distal to target arteriotomy site based on pre-procedure CT angiography. * Females who are pregnant or lactating or in fertile period not taking adequate contraceptives. A pregnancy test may be performed. * Patients that have a lower extremity amputation from the ipsilateral or contralateral limb. * Arterial access other than common femoral artery obtained for ipsilateral target leg. * Subject has a tissue tract expected to be greater than 10 cm. * Use of thrombolytic agents within 24 hours prior to or during the endovascular procedure which causes fibrinogen \< 100 mg/dl. * Significant blood loss/transfusion (defined as requiring transfusion of 4 or more units of blood products) during index procedure or within 30 days prior to index procedure. * Activated clotting time (ACT) \> 350 seconds immediately prior to sheath removal or if ACT measurements are expected to be \> 350 seconds for more than 24 hours after index procedure. * Target puncture site is located in a vascular graft. * Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 10 mm proximal of the bifurcation of the Superficial Femoral /Profunda Femoris artery. * PerQseal® Introducer-sheath to ipsilateral femoral artery diameter ratio is greater than or equal to 1.05. * Subjects with an acute haematoma of any size, arteriovenous fistula or pseudoaneurysm at the target access site; or angiographic evidence of arterial laceration or dissection within the external iliac or femoral artery before the use of the PerQseal® closure device.